Fact Source: Financial Supervisory Service DART / 2025-12-22
Disclosure Type: Execution of Single Sales/Supply Contract
💡 3-Second Summary
Samsung Biologics has signed a massive pharmaceutical Contract Manufacturing Organization (CMO) agreement worth approximately KRW 1.11T (USD 751.61M) with a European pharmaceutical company. This large-scale order accounts for 24.42% of its recent annual revenue, and the contract period runs for approximately 5 years until the end of 2030.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Contract Category & Title: Other Sales/Supply Contract / Contract Manufacturing Agreement for Pharmaceuticals
- Contract Amount: KRW 1,110,278,292,000 (Converted from the fixed contract value of USD 751,610,000 using the initial base exchange rate of KRW 1,477.20/USD as of December 19, 2025)
- Ratio to Revenue: 24.42% (Compared to the recent revenue of KRW 4,547,322,176,421 from the 2024 consolidated financial statements)
- Counterparty & Supply Region: A pharmaceutical company located in Europe (Identity and specific supply region are temporarily withheld due to operational confidentiality requirements; confidentiality expiration date is set to 2030-12-31)
- Contract Period: Start Date: 2025-12-19 ~ End Date: 2030-12-31 (Approximately 5 years)
- Contract (Order) Date: 2025-12-19
- Key Contract Terms: Down payment or advance payment is none (No). Specific payment terms are not provided in the disclosure text.
- Other Details: The contract expiration date and the information disclosure withholding period may change subject to mutual agreement. The disclosure does not state specific reasons for the change in earnings performance.
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing highlights a vital fundamental milestone confirming that Samsung Biologics has secured a mega-scale order exceeding KRW 1T within its core CMO business. Representing nearly a quarter (24.42%) of its recent annual revenue and structured to be recognized over a 5-year period, this contract carries a potential impact that may support stable mid-to-long-term top-line expansion and predictable revenue streams.
However, despite the massive scale of the order, the advance payment parameter is recorded as ‘None’, indicating no immediate upfront cash inflow, and the absence of detailed payment terms remains an information restriction for public evaluation. Furthermore, the complete non-disclosure of the counterparty’s identity and specific region until the end of 2030 due to business confidentiality limits immediate portfolio verification. Since this contract is denominated in USD, minor adjustments in KRW-converted figures may occur depending on future foreign exchange rate movements at the time of actual production and revenue recognition. Investors should evaluate this disclosure based on the long-term order backlog expansion rather than drawing short-term assumptions on immediate quarterly margin volatility.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics’ latest supply contract disclosure underscores the company’s solid order backlog strength and market competitiveness within the global CDMO industry. Securing a long-term contract worth KRW 1.11T from a European pharmaceutical company, which accounts for 24.42% of recent annual revenue, provides a potential fundamental catalyst that may support stable manufacturing capacity utilization over the next five years. Although operational confidentiality clauses will keep the client’s identity veiled until 2030 and there is no upfront down payment, the sheer volume of this secured backlog serves as a significant driver for mid-to-long-term corporate growth. Global investors should look past potential fluctuations from foreign exchange rates and focus on tracking the execution velocity of the manufacturing roadmap across facilities moving forward.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
